NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Zag Bio

Zag Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://zagbio.com/

Last Round

Series A

Oct 28, 2025

Total Funding Raised

$80M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Zag Bio is a biotechnology company that develops thymus-targeted medicines for autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

autoimmune diseasethymus targetingbifunctional antibodiesType 1 diabetesimmune toleranceimmunotherapycentral immune tolerancetherapeutic platformimmune reprogrammingimmune resetbiologicsdrug deliveryantigen delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zag Bio Comps

Public and private peers based on sector, stage, and business model.

Zag Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Zag Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 28, 2025

Key People

Founding team and executive leadership

Jason Cole

Chief Executive Officer and Board Member

Executive Team

Alison Conlon

Chief Operating Officer

Executive Team

Zag Bio Investors

Notable investors and investment history

Zag Bio investors
InvestorRounds
Boxer CapitalSeries A
Codon CapitalSeries A
GaingelsSeries A
Pear VCSeries A
AbbVie VenturesSeries A
Alexandria Venture InvestmentsSeries A
Sanofi VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 27, 2026

    Appointed Jan Hillson, M.D., with 20+ years of clinical development experience.

  • Jan 27, 2026

    Jason Cole steps down, Jan appointed as new CEO.

Zag Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Zag Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Zag Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range26
Year Founded2022
Last FundingOct 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.